| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
- Hellmich, Bernhard, et al.
(författare)
-
2018 Update of the EULAR recommendations for the management of large vessel vasculitis
- 2020
-
Ingår i: Annals of the Rheumatic Diseases. - : BMJ. - 0003-4967 .- 1468-2060. ; 79:1, s. 19-30
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Since the publication of the European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) in 2009, several relevant randomised clinical trials and cohort analyses have been published, which have the potential to change clinical care and therefore supporting the need to update the original recommendations. Methods: Using EULAR standardised operating procedures for EULAR-endorsed recommendations, the EULAR task force undertook a systematic literature review and sought opinion from 20 experts from 13 countries. We modified existing recommendations and created new recommendations. Results: Three overarching principles and 10 recommendations were formulated. We recommend that a suspected diagnosis of LVV should be confirmed by imaging or histology. High dose glucocorticoid therapy (40-60 mg/day prednisone-equivalent) should be initiated immediately for induction of remission in active giant cell arteritis (GCA) or Takayasu arteritis (TAK). We recommend adjunctive therapy in selected patients with GCA (refractory or relapsing disease, presence of an increased risk for glucocorticoid-related adverse events or complications) using tocilizumab. Methotrexate may be used as an alternative. Non-biological glucocorticoid-sparing agents should be given in combination with glucocorticoids in all patients with TAK and biological agents may be used in refractory or relapsing patients. We no longer recommend the routine use of antiplatelet or anticoagulant therapy for treatment of LVV unless it is indicated for other reasons. Conclusions: We have updated the recommendations for the management of LVV to facilitate the translation of current scientific evidence and expert opinion into better management and improved outcome of patients in clinical practice.
|
|
| 6. |
- Hellmich, Bernhard, et al.
(författare)
-
EULAR recommendations for the management of ANCA-associated vasculitis : 2022 update
- 2024
-
Ingår i: Annals of the Rheumatic Diseases. - : BMJ. - 0003-4967 .- 1468-2060. ; 83:1, s. 30-47
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Since the publication of the EULAR recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in 2016, several randomised clinical trials have been published that have the potential to change clinical care and support the need for an update. Methods: Using EULAR standardised operating procedures, the EULAR task force undertook a systematic literature review and sought opinion from 20 experts from 16 countries. We modified existing recommendations and created new recommendations. Results: Four overarching principles and 17 recommendations were formulated. We recommend biopsies and ANCA testing to assist in establishing a diagnosis of AAV. For remission induction in life-threatening or organ-threatening AAV, we recommend a combination of high-dose glucocorticoids (GCs) in combination with either rituximab or cyclophosphamide. We recommend tapering of the GC dose to a target of 5 mg prednisolone equivalent/day within 4-5 months. Avacopan may be considered as part of a strategy to reduce exposure to GC in granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). Plasma exchange may be considered in patients with rapidly progressive glomerulonephritis. For remission maintenance of GPA/MPA, we recommend rituximab. In patients with relapsing or refractory eosinophilic GPA, we recommend the use of mepolizumab. Azathioprine and methotrexate are alternatives to biologics for remission maintenance in AAV. Conclusions: In the light of recent advancements, these recommendations provide updated guidance on AAV management. As substantial data gaps still exist, informed decision-making between physicians and patients remains of key relevance.
|
|
| 7. |
- Ramisch, Carlos, et al.
(författare)
-
Edition 1.2 of the PARSEME Shared Task on Semi-supervised Identification of Verbal Multiword Expressions
- 2020
-
Ingår i: Proceedings of the Joint Workshop on Multiword Expressions and Electronic Lexicons. ; , s. 107-118
-
Konferensbidrag (refereegranskat)abstract
- We present edition 1.2 of the PARSEME shared task on identification of verbal multiword expressions (VMWEs). Lessons learned from previous editions indicate that VMWEs have low ambiguity, and that the major challenge lies in identifying test instances never seen in the training data. Therefore, this edition focuses on unseen VMWEs. We have split annotated corpora so that the test corpora contain around 300 unseen VMWEs, and we provide non-annotated raw corpora to be used by complementary discovery methods. We released annotated and raw corpora in 14 languages, and this semi-supervised challenge attracted 7 teams who submitted 9 system results. This paper describes the effort of corpus creation, the task design, and the results obtained by the participating systems, especially their performance on unseen expressions.
|
|
| 8. |
- Ren, Peng, et al.
(författare)
-
An Atomically Dispersed Mn-Photocatalyst for Generating Hydrogen Peroxide from Seawater via the Water Oxidation Reaction (WOR)
- 2023
-
Ingår i: Journal of the American Chemical Society. - 0002-7863 .- 1520-5126. ; 145:30, s. 16584-16596
-
Tidskriftsartikel (refereegranskat)abstract
- In this work, we have fabricatedan aryl amino-substitutedgraphiticcarbon nitride (g-C3N4) catalyst with atomicallydispersed Mn capable of generating hydrogen peroxide (H2O2) directly from seawater. This new catalyst exhibitedexcellent reactivity, obtaining up to 2230 & mu;M H2O2 in 7 h from alkaline water and up to 1800 & mu;Mfrom seawater under identical conditions. More importantly, the catalystwas quickly recovered for subsequent reuse without appreciable lossin performance. Interestingly, unlike the usual two-electron oxygenreduction reaction pathway, the generation of H2O2 was through a less common two-electron water oxidation reaction(WOR) process in which both the direct and indirect WOR processesoccurred; namely, photoinduced h(+) directly oxidized H2O to H2O2 via a one-step 2e(-) WOR, and photoinduced h(+) first oxidized a hydroxide (OH-) ion to generate a hydroxy radical ((OH)-O-& BULL;), and H2O2 was formed indirectly by thecombination of two (OH)-O-& BULL;. We have characterized thematerial, at the catalytic sites, at the atomic level using electronparamagnetic resonance, X-ray absorption near edge structure, extendedX-ray absorption fine structure, high-resolution transmission electronmicroscopy, X-ray photoelectron spectroscopy, magic-angle spinningsolid-state NMR spectroscopy, and multiscale molecular modeling, combiningclassical reactive molecular dynamics simulations and quantum chemistrycalculations.
|
|
| 9. |
- Savary, Agata, et al.
(författare)
-
PARSEME Corpus Release 1.3
- 2023
-
Ingår i: Proceedings of the 19th Workshop on Multiword Expressions (MWE 2023). - Stroudsburg : Association for Computational Linguistics. - 9781959429593 ; , s. 24-35
-
Konferensbidrag (refereegranskat)abstract
- We present version 1.3 of the PARSEME multilingual corpus annotated with verbal multiword expressions. Since the previous version, new languages have joined the undertaking of creating such a resource, some of the already existing corpora have been enriched with new annotated texts, while others have been enhanced in various ways. The PARSEME multilingual corpus represents 26 languages now. All monolingual corpora therein use Universal Dependencies v.2 tagset. They are (re-)split observing the PARSEME v.1.2 standard, which puts impact on unseen VMWEs. With the current iteration, the corpus release process has been detached from shared tasks; instead, a process for continuous improvement and systematic releases has been introduced.
|
|
